Generic AIDS drugs
Merck grants license to South African firm for a generic version of the AIDS drug Sustiva, but it is unclear whether efavirenz can be produced "at a price that is at or below the Merck no-profit price," Merck exec says during a conference sponsored by the American Enterprise Institute in Washington, D.C. May 12. FDA is working on a guidance on a streamlined approval process for generic AIDS treatments used in developing countries...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.